These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29608923)

  • 1. Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia.
    Newcombe AA; Gibson BES; Keeshan K
    Exp Hematol; 2018 Jul; 63():1-11. PubMed ID: 29608923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
    Ungerstedt JS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
    Kim TK; Gore SD; Zeidan AM
    Semin Hematol; 2015 Jul; 52(3):172-83. PubMed ID: 26111464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecularly targeted therapy in acute myeloid leukemia.
    Gill H; Leung AY; Kwong YL
    Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
    Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
    Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
    Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic therapy restores normal hematopoiesis in a zebrafish model of NUP98-HOXA9-induced myeloid disease.
    Deveau AP; Forrester AM; Coombs AJ; Wagner GS; Grabher C; Chute IC; Léger D; Mingay M; Alexe G; Rajan V; Liwski R; Hirst M; Steigmaier K; Lewis SM; Look AT; Berman JN
    Leukemia; 2015 Oct; 29(10):2086-97. PubMed ID: 26017032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.
    Larmonie NSD; Arentsen-Peters TCJM; Obulkasim A; Valerio D; Sonneveld E; Danen-van Oorschot AA; de Haas V; Reinhardt D; Zimmermann M; Trka J; Baruchel A; Pieters R; van den Heuvel-Eibrink MM; Zwaan CM; Fornerod M
    Oncogene; 2018 Jan; 37(1):107-115. PubMed ID: 28892045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
    Xu QY; Yu L
    Chin Med J (Engl); 2020 Mar; 133(6):699-715. PubMed ID: 32044818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Stahl M; Gore SD; Vey N; Prebet T
    Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications.
    Yang X; Wong MPM; Ng RK
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.
    Prokocimer M; Molchadsky A; Rotter V
    Blood; 2017 Aug; 130(6):699-712. PubMed ID: 28607134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
    Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C
    Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.
    Wouters BJ; Delwel R
    Blood; 2016 Jan; 127(1):42-52. PubMed ID: 26660432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panobinostat for the treatment of acute myelogenous leukemia.
    Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies.
    Lee E; Koh Y; Hong J; Eom HS; Yoon SS
    J Korean Med Sci; 2021 Apr; 36(13):e85. PubMed ID: 33821592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategies for relapsed acute myeloid leukemia: fertile ground for translational research.
    Dinner SN; Giles FJ; Altman JK
    Curr Opin Hematol; 2014 Mar; 21(2):79-86. PubMed ID: 24419335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
    Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
    Hou HA; Tien HF
    Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.